20770-65-4 (b-D-吡喃葡萄糖苷,(1aR,1bS,2S,5aS,6R,6aS)-1a,1b,2,5a,6,6a-六氢-5a,6-二羟基-1a-甲氧基并[4,5]环戊并[1,2-c]吡喃-2-基,b-D-Glucopyranoside,(1aR,1bS,2S,5aS,6R,6aS)-1a,1b,2,5a,6,6a-hexahydro-5a,6-dihydroxy-1a-methyloxireno[4,5]cyclopenta[1,2-c]pyran-2-yl)

CAS号:
20770-65-4
中文名称:
b-D-吡喃葡萄糖苷,(1aR,1bS,2S,5aS,6R,6aS)-1a,1b,2,5a,6,6a-六氢-5a,6-二羟基-1a-甲氧基并[4,5]环戊并[1,2-c]吡喃-2-基
英文名称:
b-D-Glucopyranoside,(1aR,1bS,2S,5aS,6R,6aS)-1a,1b,2,5a,6,6a-hexahydro-5a,6-dihydroxy-1a-methyloxireno[4,5]cyclopenta[1,2-c]pyran-2-yl
分子式:
C15H22O10
分子量:
362.329185962677

b-D-吡喃葡萄糖苷,(1aR,1bS,2S,5aS,6R,6aS)-1a,1b,2,5a,6,6a-六氢-5a,6-二羟基-1a-甲氧基并[4,5]环戊并[1,2-c]吡喃-2-基(20770-65-4)名称与标识符

名称

英文别名:
b-D-Glucopyranoside,(1aR,1bS,2S,5aS,6R,6aS)-1a,1b,2,5a,6,6a-hexahydro-5a,6-dihydroxy-1a-methyloxireno[4,5]cyclopenta[1,2-c]pyran-2-yl;(2S,3R,4S,5S,6R)-2-[[(1aR,1bS,2S,5aS,6R,6aS)-5a,6-dihydroxy-1a-methyl-1b,2,6,6a-tetrahydrooxireno[1,2]cyclopenta[4,5-b]pyran-2-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol;b-D-Glucopyranoside,(1aR,1bS,2S,5aS,6R,6aS)-1a,1b,2,5a,6,6a-hexahydro-5a,6-dihydroxy-1a-methyloxireno[4,5]cyclopenta[1,2-c]py;Anthirrinoside;Antirrhinoside;beta-D-glucopyranoside, (1aR,1bS,2S,5aS,6R,6aS)-1a,1b,2,5a,6,6a-hexahydro-5a,6-dihydroxy-1a-methyloxireno[4,5]cyclopenta[1,2-c]pyran-2-yl;CHEBI:2765;Q27105811;CHEMBL364464;DTXSID40331825;(2S,3R,4S,5S,6R)-2-[[(1aR,1bS,2S,5aS,6R,6aS)-5a,6-dihydroxy-1a-methyl-1b,2,6,6a-tetrahydrooxireno[1,2]cyclopenta[4,5-b]pyran-2-yl]oxy]-6-(hydroxymethyl)tetrahydropyran-3,4,5-triol;AC1L9CS5;C09768;20770-65-4;(2S,3R,4S,5S,6R)-2-[[(1S,2R,4S,5R,6S,10S)-5,6-dihydroxy-2-methyl-3,9-dioxatricyclo[4.4.0.02,4]dec-7-en-10-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol;Antirrinoside;(-)-Antirrinoside;Procumbide;

标识符

InChIKey:
UBAIOTDKPLIEDD-RNCITLLOSA-N
Inchi:
1S/C15H22O10/c1-14-9-13(22-3-2-15(9,21)10(20)11(14)25-14)24-12-8(19)7(18)6(17)5(4-16)23-12/h2-3,5-13,16-21H,4H2,1H3/t5-,6-,7+,8-,9-,10-,11+,12+,13+,14-,15+/m1/s1
SMILES:
O1[C@H]2[C@H]([C@@]3(C=CO[C@H]([C@@H]3[C@@]12C)O[C@H]1[C@@H]([C@H]([C@@H]([C@@H](CO)O1)O)O)O)O)O

b-D-吡喃葡萄糖苷,(1aR,1bS,2S,5aS,6R,6aS)-1a,1b,2,5a,6,6a-六氢-5a,6-二羟基-1a-甲氧基并[4,5]环戊并[1,2-c]吡喃-2-基(20770-65-4)物化性质

计算特性

  • 精确分子量 : 362.12129689g/mol
  • 氢键供体数量 : 6
  • 氢键受体数量 : 10
  • 可旋转化学键数量 : 3
  • 同位素质量 : 362.12129689g/mol
  • 重原子数量 : 25
  • 复杂度 : 571
  • 同位素原子数量 : 0
  • 确定原子立构中心数量 : 11
  • 不确定原子立构中心数量 : 0
  • 确定化学键立构中心数量 : 0
  • 不确定化学键立构中心数量 : 0
  • 共价键单元数量 : 1
  • 疏水参数计算参考值(XlogP) : -3.2
  • 拓扑分子极性表面积 : 162Ų

b-D-吡喃葡萄糖苷,(1aR,1bS,2S,5aS,6R,6aS)-1a,1b,2,5a,6,6a-六氢-5a,6-二羟基-1a-甲氧基并[4,5]环戊并[1,2-c]吡喃-2-基(20770-65-4)相关文献